SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models

por Mazahreh, Rebecca, Mason, Marsha L., Gosink, John J., Olson, Devra J., Thurman, Robert, Hale, Christopher, Westendorf, Lori, Pires, Thomas A., Leiske, Christopher I., Carlson, Markus, Nguyen, Liem T., Cochran, Julia H., Okeley, Nicole M., Yumul, Roma, Jin, Steven, Stone, Ivan J., Sahetya, Disha, Nesterova, Albina, Allred, Sean, Hensley, Kelly M., Hu, Rachael, Lawrence, Robert, Lewis, Timothy S., Sandall, Sharsti
Publicado 2023

De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2

por Linsky, Thomas W., Vergara, Renan, Codina, Nuria, Nelson, Jorgen W., Walker, Matthew J., Su, Wen, Barnes, Christopher O., Hsiang, Tien-Ying, Esser-Nobis, Katharina, Yu, Kevin, Reneer, Z. Beau, Hou, Yixuan J., Priya, Tanu, Mitsumoto, Masaya, Pong, Avery, Lau, Uland Y., Mason, Marsha L., Chen, Jerry, Chen, Alex, Berrocal, Tania, Peng, Hong, Clairmont, Nicole S., Castellanos, Javier, Lin, Yu-Ru, Josephson-Day, Anna, Baric, Ralph S., Fuller, Deborah H., Walkey, Carl D., Ross, Ted M., Swanson, Ryan, Bjorkman, Pamela J., Gale, Michael, Blancas-Mejia, Luis M., Yen, Hui-Ling, Silva, Daniel-Adriano
Publicado 2020